Can-Fite Biopharma Ltd Sponsored ADR (Israel)

News & Events

Press Releases

In The Media

1. Can-Fite Has Raised $175 Million in Total to Date for the Development of Namodenoson and Piclidenoson, Advancing into Pivotal Phase 3 Trials in Liver Cancer and Psoriasis

   GlobeNewswire MAY 5, 2025 8:00 AM EDT
   Ramat Gan, Israel, May 05, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF)...
   READ ARTICLE

2. Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients

   GlobeNewswire APR 17, 2025 8:55 AM EDT
   Ramat Gan, Israel, April 17, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American:...
   READ ARTICLE

3. Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares

   GlobeNewswire APR 14, 2025 2:28 PM EDT
   RAMAT GAN, Israel, April 14, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CAN...
   READ ARTICLE

4. Can-Fite to Generate $685M in Projected Future Revenues from its Partnerships

   GlobeNewswire APR 14, 2025 8:30 AM EDT
   Ramat Gan, Israel, April 14, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CAN...
   READ ARTICLE

5. Can-Fite Reports 2024 Financial Results and Clinical Update

   GlobeNewswire APR 14, 2025 8:00 AM EDT
   RAMAT GAN, Israel, April 14, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American:...
   READ ARTICLE

6. Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol

   GlobeNewswire MAR 24, 2025 9:00 AM EDT
   The psoriasis market is estimated at $30 Billion by 2030 and has shifted significantly to oral dr...
   READ ARTICLE

7. Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market

   GlobeNewswire MAR 20, 2025 9:45 AM EDT
   Can-Fite’s upfront and royalties on sales upon regulatory approval of Piclidenoson for vet...
   READ ARTICLE

8. Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson

   GlobeNewswire MAR 19, 2025 9:00 AM EDT
   FDA & EMA approvals for rare genetic diseases are fast and require clinical studies with smal...
   READ ARTICLE

9. Can-Fite: FDA Approved Compassionate Use Treatment with Namodenoson in a Pancreatic Cancer Patient

   GlobeNewswire MAR 18, 2025 8:30 AM EDT
   Ramat Gan, Israel, March 18, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American:...
   READ ARTICLE

10. Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits

    GlobeNewswire MAR 3, 2025 6:00 AM EST
    Unlike chemotherapy with its known toxicity towards normal body systems, Namodenoson provides pro...
    READ ARTICLE